Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 52, n° 6
pages 991-996 (juin 2005)
Doi : 10.1016/j.jaad.2005.02.055

Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: Development of extracutaneous lymphoma in 6 patients

Saskia A. Bouwhuis, MD a, Mark D.P. Davis, MD a, , Rokea A. el-Azhary, MD a, Marian T. McEvoy, MD a, Lawrence E. Gibson, MD a, John M. Knudsen, MD b, Joseph M. Kist, MD a, Mark R. Pittelkow, MD a
a From the Departments of Dermatology 
b Radiology, Mayo Clinic 

Correspondence to: Mark D. P. Davis, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.

Rochester, Minnesota


Bexarotene is a retinoid drug that is approved for the treatment of cutaneous T-cell lymphoma. We report 6 cases in which the initiation of bexarotene therapy for cutaneous T-cell lymphoma was temporally associated with the progression of internal disease despite improvement in cutaneous signs and symptoms. It is possible that bexarotene contributed to this progression. Although bexarotene therapy may alleviate symptoms and signs of cutaneous T-cell lymphoma, careful surveillance of lymph nodes and solid organs during treatment is advised.

The full text of this article is available in PDF format.

 Funding sources: None.
Conflicts of interest: None.
Nothing in this article implies endorsement of the products of Ligand Pharmaceuticals.

  This patient participated in the multicenter clinical trials of bexarotene therapy for late-stage cutaneous T-cell lymphoma that were supported by Ligand Pharmaceuticals, San Diego, California; a more detailed account of this patient has been published separately (el-Azhary RA, Bouwhuis SA. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization. Int J Dermatol 2005;44:25-8.)

© 2005  American Academy of Dermatology, Inc.@@#104156@@